Strategic Collaborations Tavros Therapeutics, now part of Vividion, is actively partnering with pharma and biotech to discover small molecule modulators for oncology targets, including recent deals with Bayer/Vividion and OpenBench. This indicates a strong appetite for expanded collaboration models; BD pitch: offer co-development licenses, expanded target sets, and integrated discovery programs to accelerate milestones.

Target Discovery Focus The company specializes in unlocking high-value, traditionally undruggable oncology targets using novel discovery technologies, with a track record of multi-target collaborations (up to five oncology targets with OpenBench; four targets with Vividion). This creates opportunities to present services around target validation, assay development, and lead discovery for pharma partners seeking novel targets.

Platform and Data As a functional genomics platform company, Tavros seeks to leverage data-rich discovery to identify four oncology targets and beyond. A sales angle: offer data licensing, AI-driven target prioritization, screening data, and access to proprietary platform capabilities under multi-year partnerships or select licensing deals.

Growth and Funding With seed financing totaling millions and ongoing revenue, Tavros/Vividion sits in an investment-ready, growth phase where milestone-based collaborations, CRO-style services, or platform licensing can be attractive options for partners seeking to share risk and secure early access to innovative discovery capabilities.

Regional Advantage Based in Durham, NC, Tavros operates within a growing US biotech cluster with potential local partnerships and access to regional talent and academic networks. GTM approach: leverage NC ecosystem for co-development pilots, contract services, and regional partnerships to scale quickly.